Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial.
Jennifer HendrickJennie Z MaHeather M HaugheyRachael ColemanUma NayakAlexandra KadlJeffrey M SturekPatrick E H JacksonMary K YoungJudith E AllenWilliam A PetriPublished in: Open forum infectious diseases (2024)
In this observational study, subjects who received dupilumab during acute COVID-19 hospitalization were less likely to have a reduced DLCO or 6MWT, with a nonsignificant trend toward reduced mortality at 1 year compared to placebo.
Keyphrases
- coronavirus disease
- liver failure
- atopic dermatitis
- respiratory failure
- drug induced
- phase iii
- aortic dissection
- clinical trial
- respiratory syndrome coronavirus
- study protocol
- cardiovascular events
- risk factors
- type diabetes
- randomized controlled trial
- cardiovascular disease
- intensive care unit
- double blind
- free survival
- placebo controlled